Beyond Air (XAIR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 May, 2026Executive summary
Special Meeting scheduled for June 18, 2026, to vote on a reverse stock split and potential adjournment if more votes are needed.
The reverse stock split aims to increase the share price to meet Nasdaq's $1.00 minimum bid price requirement and avoid delisting.
The Board has discretion to set the split ratio between 1-for-2 and 1-for-20 at any time within one year of the meeting.
If delisted from Nasdaq, shares may trade OTC, which could reduce liquidity and access to capital.
The Board recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1: Approve an amendment to effect a reverse stock split at a ratio of 1-for-2 to 1-for-20, at the Board's discretion.
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes for Proposal 1.
Both proposals are considered routine matters, allowing brokers to vote uninstructed shares.
Approval of Proposal 1 requires a majority of shares present and entitled to vote.
Board of directors and corporate governance
The Board has full discretion to determine if and when to implement the reverse split within one year of approval.
No other matters are expected to be presented at the meeting.
Latest events from Beyond Air
- Tankless nitric oxide therapy platform drives rapid growth and global market expansion.XAIR
Corporate presentation - Generation 2 device approval is set to unlock a $400M+ market with immediate deployment planned.XAIR
12th Annual Cantor Fitzgerald Global Healthcare Conference - Up to 5.4M shares registered for resale after a $10.2M private placement; focus on LungFit® growth.XAIR
Registration filing - Flat revenue, improved margins, and strong outlook depend on FDA approval and new product launch.XAIR
Q1 2027 - Revenue up 107% to $7.7M; Gen 2 launch and approval expected to drive major growth in 2027.XAIR
Q4 2026 - Vote on a reverse stock split to maintain Nasdaq listing and authorize meeting adjournment if needed.XAIR
Proxy filing - Patented tankless NO technology drives rapid growth and pipeline expansion in respiratory and oncology markets.XAIR
Corporate presentation - Q3 revenue up 105% YoY, net loss narrowed, and global expansion continues.XAIR
Q3 2026 - Next-generation system and global partnerships position the company for accelerated growth by 2027.XAIR
Piper Sandler 36th Annual Healthcare Conference